Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCALIBER-RRMM phase 3 trial of iberdomide + daratumumab + dexamethasone versus daratumumab + bortezomib + dexamethasone in relapsed or refractory multiple myeloma
MOH_2022-02-13_010605Phase 3Not yet recruiting
- Sponsor
- Celgene Corporation
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Iberdomide + daratumumab + dexamethasone with Daratumumab + bortezomib + dexamethasone (2 arms). Planned start Sep 2021; status: not yet recruiting.
02
Drugs
iberdomidedaratumumabbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2022-02-13_010605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-02-13_010605.